Latest Regulatory Approvals News

Challenger reports a solid first half of FY26 with rising profits, strong annuity sales, and strategic partnerships, underpinning a confident outlook and a $150 million share buy-back plan.

Qube Holdings has inked a scheme implementation deed with a Macquarie Asset Management-led consortium, valuing the company at approximately $11.7 billion and offering shareholders a 27.8% premium. The deal, subject to regulatory and shareholder approvals, sets the stage for a significant shift in the Australian logistics landscape.

Clarity Pharmaceuticals’ Cu-64 SAR-bisPSMA diagnostic agent significantly outperformed the current standard Ga-68 PSMA-11 in detecting prostate cancer recurrence, more than doubling lesion and patient detection rates in a pivotal head-to-head trial.

Red Mountain Mining has initiated metallurgical test work on high-grade samples from its Oaky Creek Antimony Prospect, advancing the Armidale Antimony-Gold Project towards commercial validation. This move aims to de-risk the asset ahead of drilling and capitalise on strong early exploration results.

Strike Energy has secured all regulatory approvals to drill the Walyering West-1 well in the Perth Basin, aiming to unlock a prospective 46 PJ gas resource with drilling set to commence by mid-April 2026.

Sunshine Metals has released a comprehensive scoping study for its Liontown Gold Operation in North Queensland, outlining a promising initial production target of approximately 75,000 ounces of gold and 654,000 ounces of silver. The study highlights strong financial metrics and a pathway to production by late 2026, with further resource updates expected.

Forrestania Resources has agreed to acquire MacPhersons Reward, consolidating its Coolgardie gold tenure with a $5 million cash and share deal that supports its shift from explorer to near-term producer.

Finder Energy has successfully completed the Front-End Engineering Design for its Kuda Tasi and Jahal subsea development, setting the stage for a Final Investment Decision by mid-2026.

The a2 Milk Company has reported robust half-year results with strong revenue and earnings growth, driven by gains in infant formula and liquid milk segments, alongside a strategic supply chain transformation. The company has upgraded its full-year outlook and announced a substantial special dividend, signalling confidence in its growth trajectory.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.

St George Mining has won preferential tax treatment from the Minas Gerais government, cutting development costs for its flagship Araxá Project in Brazil. This support bolsters the company’s ambitions to establish a world-class niobium and rare earths operation.